Jeil Pharm
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms i… Read more
Jeil Pharm (002620) - Total Assets
Latest total assets as of September 2025: ₩860.96 Billion KRW
Based on the latest financial reports, Jeil Pharm (002620) holds total assets worth ₩860.96 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Jeil Pharm - Total Assets Trend (2011–2024)
This chart illustrates how Jeil Pharm’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Jeil Pharm - Asset Composition Analysis
Current Asset Composition (December 2024)
Jeil Pharm's total assets of ₩860.96 Billion consist of 46.0% current assets and 54.0% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 6.7% |
| Accounts Receivable | ₩188.18 Billion | 21.1% |
| Inventory | ₩123.67 Billion | 13.9% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩13.76 Billion | 1.6% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Jeil Pharm's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jeil Pharm's current assets represent 46.0% of total assets in 2024, a decrease from 67.1% in 2011.
- Cash Position: Cash and equivalents constituted 6.7% of total assets in 2024, up from 5.9% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, unchanged from 1.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 21.1% of total assets.
Jeil Pharm Competitors by Total Assets
Key competitors of Jeil Pharm based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Jeil Pharm - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Jeil Pharm generates 0.88x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Jeil Pharm is currently not profitable relative to its asset base.
Jeil Pharm - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.15 | 1.01 | 1.02 |
| Quick Ratio | 0.79 | 0.66 | 0.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩47.12 Billion | ₩ 4.97 Billion | ₩ 7.76 Billion |
Jeil Pharm - Advanced Valuation Insights
This section examines the relationship between Jeil Pharm's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.44 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 1.2% |
| Total Assets | ₩890.43 Billion |
| Market Capitalization | $13.28 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jeil Pharm's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Jeil Pharm's assets grew by 1.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Jeil Pharm (2011–2024)
The table below shows the annual total assets of Jeil Pharm from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩890.43 Billion | +1.19% |
| 2023-12-31 | ₩880.00 Billion | +1.65% |
| 2022-12-31 | ₩865.68 Billion | -3.00% |
| 2021-12-31 | ₩892.42 Billion | +0.57% |
| 2020-12-31 | ₩887.40 Billion | +4.83% |
| 2019-12-31 | ₩846.47 Billion | -8.00% |
| 2018-12-31 | ₩920.09 Billion | +365.66% |
| 2017-12-31 | ₩197.59 Billion | -59.84% |
| 2016-12-31 | ₩491.98 Billion | +10.52% |
| 2015-12-31 | ₩445.17 Billion | +13.92% |
| 2012-12-31 | ₩390.77 Billion | +1.73% |
| 2011-12-31 | ₩384.13 Billion | -- |